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In Silico Analysis Identifies a Novel Role for
Androgens in the Regulation of Human Endometrial
Apoptosis
Elaine Marshall, Jacqueline Lowrey, Sheila MacPherson, Jacqueline A. Maybin,
Frances Collins, Hilary O. D. Critchley, and Philippa T. K. Saunders
Medical Research Council/University of Edinburgh Centre for Reproductive Health, The University of
Edinburgh, The Queen’s Medical Research Institute, Edinburgh EH16 4TJ, United Kingdom
Context: The endometrium is a multicellular, steroid-responsive tissue that undergoes dynamic
remodeling every menstrual cycle in preparation for implantation and, in absence of pregnancy,
menstruation. Androgen receptors are present in the endometrium.
Objective: The objective of the study was to investigate the impact of androgens on human en-
dometrial stromal cells (hESC).
Design: Bioinformatics was used to identify an androgen-regulated gene set and processes asso-
ciated with their function. Regulation of target genes and impact of androgens on cell function
were validated using primary hESC.
Setting: The study was conducted at the University Research Institute.
Patients: Endometrium was collected from women with regular menses; tissues were used for
recovery of cells, total mRNA, or protein and for immunohistochemistry.
Results: A new endometrial androgen target gene set (n  15) was identified. Bioinformatics
revealed 12 of these genes interacted in one pathway and identified an association with control
of cell survival. Dynamic androgen-dependent changes in expressionof thegene setweredetected
in hESC with nine significantly down-regulated at 2 and/or 8 h. Treatment of hESC with dihy-
drotestosterone reduced staurosporine-induced apoptosis and cell migration/proliferation.
Conclusions: Rigorous in silico analysis resulted in identification of a group of androgen-regulated
genes expressed in human endometrium. Pathway analysis and functional assays suggest andro-
gen-dependent changes in gene expression may have a significant impact on stromal cell prolif-
eration, migration, and survival. These data provide the platform for further studies on the role of
circulatory or local androgens in the regulation of endometrial function and identify androgens
as candidates in the pathogenesis of common endometrial disorders including polycystic ovarian
syndrome, cancer, and endometriosis. (J Clin Endocrinol Metab 96: E1746–E1755, 2011)
The human endometrium is a multicellular, steroid-tar-get tissue that undergoes dynamic remodeling during
everymenstrual cycle (1). Cell proliferation, angiogenesis,
differentiation (decidualization), and shedding (menstru-
ation) are controlled by cyclical variations in estrogen and
progesterone secreted by the ovaries. In normal women
the circulating level of androgen is higher than estrogen;
the major circulating androgens include dehydroepi-
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Abbreviations: ACSS2, Acyl-CoA synthetase short-chain family member 2; AR, androgen
receptor; CBP, cAMP response element-binding protein; ChIP, chromatin immunoprecipi-
tation; CITED2, CBP/p300-interacting transactivator 2; DHEA, dehydroepiandrosterone;
DHT, dihydrotestosterone; E2, estradiol; ER, estrogen receptor; hESC, human endometrial
stromal cell; MAOA, monoamine oxidase type A; MMP, matrix metalloproteinase; PCOS,
polycystic ovarian syndrome; PMAIP1, phorbol-12-myristate-13-acetate-induced protein
1; PRUNE2, prune homolog 2; T, testosterone.
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androsterone (DHEA) and DHEA sulfate, androstenedi-
one, and testosterone (T) (2). During the normal men-
strual cycle, androgens are secreted by the ovary and
adrenal gland with the latter the major source of DHEA
and DHEA sulfate (3). Peripheral levels of androstenedi-
one and T peak midcycle, consistent with approximately
50% being derived from ovarian tissue (3). Although cir-
culating concentrations of dihydrotestosterone (DHT) are
low, both isoforms of 5-reductase (types 1 and 2) are
expressed in endometrial epithelial cells, consistent with
the potential for local metabolism of T to DHT (4). Only
T and DHT are capable of binding with high specificity
and affinity to the androgen receptor (AR), a member of
a superfamily of ligand-activated transcription factors
that includes estrogen receptors (ER; ER, ER) and pro-
gesterone receptor (http://www.nursa.org/). In the human
endometrium, immunoexpression of AR in the functional
(upper) layer is most intense in stromal fibroblasts dur-
ing the estrogen-dominated proliferative phase (1, 4),
down-regulated during the secretory phase, but main-
tained in stromal cells within the basal compartment
throughout the cycle (Supplemental Fig. 1, published on
The Endocrine Society’s Journals Online web site at
http://jcem.endojournals.org). Expression in glandular ep-
ithelial cells is up-regulated in the functional compartment
during themid-secretoryphase andcanbedetected inboth
stromal and epithelial cells in first trimester decidua (5).
A number of lines of evidence suggest that endogenous
or exogenous androgens can alter endometrial function.
For example, higher circulating concentrations of free T
and overexpression of endometrial AR (6) have been de-
tected in women with polycystic ovarian syndrome
(PCOS), a condition associated with increased rates of
miscarriage, endometrial hyperplasia, and endometrial
cancer (7). Local intrauterine delivery of the androgenic
progestagen levonorgestrel results in decidualization of
endometrial stromal cells, atrophy of the glandular and
surface epithelium and changes in vascular morphology
(8), and administration of androgens to female transsex-
uals results in endometrial atrophy (9). The mechanisms
responsible for these androgen-dependent changes in en-
dometrial cell function remain unexplored.
To date, most studies examining the impact of andro-
gens on gene expression have been conducted using cell
lines derived from prostatic cancers. The most robust ev-
idence for direct binding of ligand-activated AR to pro-
moters of androgen-regulated genes being obtained by
combining chromatin immunoprecipitation (ChIP) with
tiled oligonucleotide microarrays (10–12). The endome-
trium, like the prostate, has a well-defined stromal com-
partment and a steroid-dependent secretory epithelium
capable of forming hormone-dependent adenocarcino-
mas. When Nantermet et al. compared data sets obtained
from array studies using the ventral prostates (13) and
uterus (14) from rats, they found a common target gene set
(n  28) regulated by DHT underlining the existence of
common androgen-regulated pathways in these two
organs.
In the current study, we screened gene data sets, per-
formed bioinformatics for promoter and pathway analy-
sis, and confirmed androgen-dependent changes in a tar-
get set of androgen-regulated genes using primary human
endometrial AR-positive stromal cells. These studies re-
vealed a novel role for androgen in endometrial cell sur-
vival and highlighted the opportunities to be gained by
bioinformatic analysis of genomic data sets from different
tissues/species.
Materials and Methods
In silico analysis of endometrial data sets and
identification of putative androgen-regulated
genes
Microarray, ChIP, and published gene data sets (Supplemental
Table 1) were recovered from the Gene Expression Omnibus
[GSE4888 (15), GSE7868 (12)] and published data sets (14, 16).
The strategy forcomparisonofdata sets isoutlined inSupplemental
Fig. 2. TheGSE4888data set included raw signal intensities; global
normalization to the 75th percentile was undertaken and all sub-
sequent calculations were done using log2-transformed values.
Fold change and false discovery rate was calculated using the
SAM (Significance Analysis Microarray software developed at
Stanford University and available free to academic users by reg-
istering at http://www-stat-class.stanford.edu/tibs/clickwrap/
sam.html.). For the data set generated from rat uterus (14), gene
identifiers were mapped on to the human ortholog. Data gener-
ated from array analyses of endometrium of normoovulatory
women (15) were processed to identify those genes differentially
expressed between the proliferative [AR immunoexpression in-
tense in stromal cells (1, 4)] and midsecretory phases; this com-
parison was not made in the original study (15). The final en-
dometrial androgen target gene set was generated by filtering for
entries overlapping between all the data sets derived from the
studies in both human and rat endometrium (14–16) and human
prostatic cells (11, 17, 18) (Supplemental Fig. 2).
Promoter and pathway analysis
Promoter regions of genes in the endometrial androgen target
gene set (Table 1) were screened for transcription factor binding
sites using MAPPER (http://bio.chip.org/mapper (19); using se-
quences 10 kb upstream and 4 kb downstream from the tran-
scription start site of each gene as retrieved from Ensemble 54
(buildNCBI36).Geneontology andbiological pathwayanalyses
were performed using MetaCore version 5.4 build 19940 (Ge-
neGo, Inc., St. Joseph, MI).
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Patients and tissues
Endometrial tissueswere collected by suction curette (n 14,
Pipelle; Laboratoire CCD, Paris, France) or after hysterectomy
(n 10) fromwomenwith regularmenstrual cycleswhohad not
received hormonal treatments during the 3 months before tissue
collection. Samples were staged based on standard histological
criteria, the patient’s reported last menstrual period, and circu-
lating estradiol (E2) and progesterone levels at the time of col-
lection. First-trimester decidua (n 4; 8–12 wk gestation) were
collected from women undergoing the surgical termination of
pregnancy.Written informed consentwas obtained fromall sub-
jects andethical approval grantedby theLothianResearchEthics
Committee. Tissues were fixed in 4%neutral buffered formalin,
immersed in RNAlater (Ambion, Austin, TX), or used for iso-
lation of primary cells.
Endometrial stromal cell culture
Primary human endometrial stromal cells (hESC) were puri-
fied from proliferative stage samples as previously described
(20). Cells were maintained at 37 C in DM-RPMI 1640 [con-
taining 10%heat inactivated fetal calf serum, penicillin (100 U),
streptomycin (0.1 mg/ml), Fungizone (1 g/ml) (Life Technolo-
gies, Inc., Paisley, UK), L-glutamine (2 mM), and gentamicin
(0.02 mg/ml)]. For gene expression studies, they were seeded at
2 105/well in six-well culture plates and allowed to reach 80%
confluence, incubated for 24 h in phenol red-free DM-RPMI
1640 (10% charcoal stripped fetal calf serum and supplements
as above) followed by 24 h in phenol red-free, serum-free me-
dium. Treatments were performed using serum-free medium
containing vehicle (ethanol) or DHT (108 M) for 2, 8, or 24 h
(n 6) for measurement of mRNA or 8, 24, or 48 h (n 6) for
measurement of protein. hESC derived from proliferative phase
endometrium express both ER and ER [(21); Collins, F., un-
published observations]; therefore, DHT was chosen for these
studies because, unlike T, it is not metabolized to E2. To ensure
that concentrations of DHT were maintained throughout the
culture period, media were refreshed after 8 h.
Gene expression analysis
Total RNA was purified using TRIzol (Invitrogen, Paisley,
UK) according to the manufacturer’s instructions; cDNA was
prepared using the SuperScript VILO cDNA synthesis kit (In-
vitrogen) using 400 ng of template RNA. PCRwas performed in
10-l reactions that contained 5.0 l of TaqMan master mix
(Applied Biosystems, Warrington, UK), 200 nM of each primer,
5 nM of probe, and 4.5 l of template (1:20 dilution of cDNA).
Details of primer/probes are given in Supplemental Table 2; PCR
was 95 C for 10 min plus 40 cycles of 95 C for 15 sec and 60 C
for 60 sec. Target genes were quantified using standard template
dilution curves and normalization to endogenous controls (18S,
actin).
Immunohistochemistry
Primary antibodies are listed in Supplemental Table 3; neg-
ative controls had nonimmune serum. Tissues sections were im-
munostained using standard protocols with antigen retrieval at
pH 6. Primary hESC were fixed in cold methanol and perme-
abilized in 0.2% IGEPAL (octylphenoxypolyethoxyethanol;
Sigma, St. Louis, MO) with 1% BSA and 10% blocking serum.
Endogenousperoxidasewasblockedusing0.15%hydrogenper-
oxide in methanol. For visualization of bound primary antibod-
ies, cells were incubated with biotinylated secondary antibodies
(goat antimouse Ig, goat antirabbit Ig, or rabbit antigoat Ig;
Dako UK Ltd., Ely, UK) diluted to 1:500 for 30 min at room
temperature followed by reagents from the ImmPACT diamino-
benzidine kit (Vector Laboratories, Burlingame, CA).
Apoptosis assay
Apoptosis was measured using the Apo-ONE homogeneous
caspase-3/7 assay kit (Promega Ltd., Hampshire, UK): the
amountof fluorescentproduct generatedwasproportional to the
amount of active caspase-3/7 in the sample. Cellswere incubated
with staurosporine (30–500nM)alone (positive control) or in the
presence of DHT, E2, or DHT plus E2 all at 108 M for 0.5–3 h.
Wound-healing assay
hESC (passage 5) were seeded at 2  105 well in six-well
plates in DM-RPMI 1640, supplemented as above, and grown
until confluent. Forty-eight hours before scratch, medium was
replaced with serum/phenol-free RPMI 1640. One hour before
the scratch, cells were pretreated for 1 h with 105 M flutamide
or medium supplemented with vehicle. Each well of cells was
scratched with a sterile 200-l pipette tip and then incubated in
the presence of DHT (108 M) or vehicle in serum-free media
(n  6 experiments, duplicate wells). For each well, six images
were captured along the lengthof eachwoundat 0 and24husing
an Axiovert 200M inverted microscope (Carl Zeiss, Jena, Ger-
many). Imageswere analyzed usingAxioVision release 4.72, and
calculations of average distance closed for each sample were
TABLE 1. Endometrium androgen target gene set identified by stringent in silico screening of publicly available data
sets
Gene ID Name Predicted change* Gene ID Name Predicted change*
NM_018677 ACSS2 Up NM_000805 GAST Down
NM_000610 CD44 Up NM_002425 MMP10 Down
NM_006079 CITED2 Up NM_006207 PDGFRL Down
NM_000115 EDNRB Up NM_021127 PMAIP1 Down
NM_005797 EVA1/MPZL2 Up NM_138818 PRUNE2 Down
NM_000187 HGD Up NM_024745 SHCBP1 Down
NM_000240 MAOA Up NM_007117 TRH Down
NM_003621 PPFIBP2 Up
ID, Identification.
*The predicted change in expression in response to androgens is based on studies in prostatic cells (22, 23).
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based on three measurements at identical positions along the
wound at 0 and 24 h.
Statistical analysis
Values presented are averages  SEM. Differences in mean
values were evaluated by an unpaired t test and two-way
ANOVA analysis using Bonferroni for post hoc comparisons.
P  0.05 was considered to be statistically significant.
Results
Identification of putative androgen target genes
expressed in human endometrium
Rigorous in silico comparisons of a gene set extracted
from molecular phenotyping of human endometrium
from normoovulatory women (15) with data sets of an-
drogen-regulated genes identified in rat uterus, decidual-
ized human cells, and androgen-responsive prostatic cell
lines (Supplemental Table 1 and Supplemental Fig. 2) re-
sulted in the identification of only 15 genes, hereafter re-
ferred to as the endometrial androgen target gene set (Ta-
ble 1). Consistent with the inclusion of genes identified by
ChIP array (11, 12) in our screening
strategy, consensus androgen response
elements were identified in the pro-
moter regions of all candidate genes
(Supplemental Fig. 3). Sequences with
homology to consensus binding sites
for other proteins implicated in steroid-
dependent changes in gene transcrip-
tion, including estrogen and progester-
one receptors, activator protein-1, and
SP-1 were also represented in the same
promoter regions (Supplemental Fig. 3).
Validation of expression of
androgen target gene set in
human endometrium and decidua
mRNA encoded by all 15 of the an-
drogen target gene set were detected in
total tissue homogenates of endometrial
tissue obtained during the proliferative
phase (Fig. 1 and data not shown) when
immunoexpression of AR is restricted
to the stromal compartment (Supple-
mental Fig. 1). Fourteen were also de-
tected in extracts of first-trimester de-
cidua (TRH, not detectable, Fig. 1, and
data not shown). Expression of phorbol-
12-myristate-13-acetate-inducedprotein
1 (PMAIP1) mRNA was higher in pro-
liferative compared with midsecretory
phase endometrium (P 0.01), whereas
the opposite result was obtained for monoamine oxidase
type A (MAOA) (Fig. 1). Using commercially available
antibodies,wewere able to confirm expression of proteins
encoded by PMAIP1, MAOA, cAMP response element-
binding protein (CBP)/p300-interacting transactivator 2
(CITED2), prune homolog 2 (PRUNE2/BNIPXL), and
CD44using sections of human endometriumanddecidua;
all four proteins were expressed in the stromal compart-
ment during the proliferative phase (Supplemental Fig. 4).
Subcellular patterns of expression in primary hESC mim-
icked those in vivo with CITED2 detected in the nucleus,
PRUNE2 localized to the cytoplasm, and PMAIP1 in both
compartments (Supplemental Fig. 5).
Regulation of target genes in primary endometrial
stromal cells by DHT is time dependent
During in vitro incubation the primary hESC retained
the phenotype of the stromal cells within the functional
layer of the proliferative phase endometrium being immu-
nopositive both CD10 [a stromal cell marker (22)] and
AR; the latter was also detected as a full-length protein on
FIG. 1. Expression of candidate androgen-regulated gene mRNA in total tissue extracts from
human endometrium and decidua as determined by quantitative RT-PCR. Samples were
homogenized from functional endometrium recovered during the proliferative (P) and
midsecretory phases (MS) as well as from first-trimester decidua (Dec). Concentrations
displayed relative to those in proliferative phase in each case (n  4–6 per group).
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Western blots (Supplemental Fig. 5). We confirmed that
expression of AR mRNA was maintained up to and in-
cluding passage 5 but thereafter declined (not shown), and
therefore, all subsequent evaluations were undertaken on
primary hESC at passages 3–5. Expression of 12 of 15 of
the endometrial target gene set was detected in primary
hESC (Fig. 2); concentrations of mRNA encoded by three
putative AR target genes [EVA1, gastrin (GAST), TRH]
were too low to be investigated further. For nine of 15 of
the genes [PMAIP1, SHC SH2 binding protein 1 (SHC
BP1), platelet-derived growth factor receptor-like (PDG-
FRL), acyl-CoA synthetase short-chain family member
2 (ACSS2), matrix metallopeptidase 10 (stromelysin
2/MMP10, CITED2, MAOA] incubation of cells with
DHT resulted in a significant reduction in their mRNA at
one ormore time points. The exceptionwasCD44, which
was increased at 2 h, returning to con-
trol levels at 8/24 h (Fig. 2).
Pathway analysis identifies
apoptosis as an androgen-
dependent process
Pathway analyses revealed 12 of 15
of the androgen target gene set inter-
acted, directly or indirectly, on one net-
work associated with androgen-regu-
lated cell function (Fig. 3) and an
association with cell death (Table 2).
Additionalbioinformaticanalysisof sub-
network interactions formed between
theandrogentargetgenesethighlighteda
relationship between AR-CD44-endo-
thelin receptor B and gastrin associated
with response to cell stress. A further as-
sociation was identified between AR-
CITED2-CD44 and PMAIP1 in control
of apoptosis (Table 3).
Functional studies confirm that
androgens may protect primary
stromal hESC against apoptosis
and reduce cell migration
The impact of DHT on apoptosis
was investigated using a caspase-3/7
fluorescent assay. Caspase activity was
notdetected in controlhESCculturesor
after treatment of cells withDHTalone
(not shown). When apoptosis was in-
duced by treatment of cells with stau-
rosporine (30–500 nM), addition of
DHT significantly reduced caspase ac-
tivation. Addition of E2 had no effect
and simultaneous addition of E2 and
DHT partially abrogated the antiapoptotic impact of the
DHT (Fig. 4A).
To determinewhether exposure to androgens could have
adirect impactonmigrationofhESC,awound-healingassay
was performed using cells pretreated with vehicle or flut-
amide that were subsequently incubated with or without
DHT for 24 h (Fig. 4B). A significant reduction in the rate of
wound healingwas detectedwhen cells were incubatedwith
DHT alone (P  0.05), whereas addition of flutamide
alone had no effect pretreatment of cells with flutamide
abrogated the impact of DHT (Fig. 4B).
Discussion
Expression of AR and enzymes capable of local biosyn-
thesis of androgenic ligands has been well documented in
FIG. 2. Time-dependent changes in androgen-regulated gene expression in primary hESC.
Cells were incubated with vehicle (gray bars) or 108 M DHT (black bars) for 2, 8, and 24 h
(n  6 each time point). Concentration of mRNA was quantified by quantitative RT-PCR and
expressed as fold change compared with time-matched vehicle-treated hESC. Note that with
the exception of CD44, incubation of cells with DHT resulted in either a significant reduction
in concentration of mRNA or no significant change but with a trend to a reduction. For most
genes, changes in mRNA expression were time dependent with the most striking change in
total concentrations at 2 h for eight of 12 of the genes. *, P  0.05; **, P  0.01; ***, P 
0.001.
E1750 Marshall et al. Androgens and Endometrium J Clin Endocrinol Metab, November 2011, 96(11):E1746–E1755
human endometrium, but little is known about the direct
impacts of androgens on gene expression in this dynamic
tissue. In this study, rigorous in silico comparisons of
genomic data sets derived from normal human endome-
trium (15) with those identified as androgen regulated by
array analysis of uteri from DHT-exposed rats (14), an-
drogen-treated human decidualized cells (16), and genes
identified as containing regions within their promoters
TABLE 2. Gene ontology processes associated with the androgen candidate gene set identified by androgen
candidate gene ontology identified using Metacore
Processes Target P value Z-score
Regulation of biological quality (57.5%), regulation of apoptosis (42.5%), regulation
of programmed cell death (42.5%)
14 5.74e-43 119.50
Regulation of biological quality (54.5%), embryonic placenta development (13.6%),
oxygen homeostasis (9.1%)
6 2.18e-16 61.16
Regulation of ion transport (27.0%), positive regulation of hydrolase activity (32.4%),
positive regulation of phospholipase activity (24.3%)
4 5.94e-10 35.52
Note that the term target indicates the number of candidate genes/proteins/compounds (objects) in a data set that are associated with a given
network/process. The P value (the probability of a random intersection) indicates a measure of relevance of the intersection between a
gene/protein and an entity in a particular ontology. The lower the P value, the higher is the nonrandomness of finding such intersection. The Z-
score ranks the networks with regard to the number of objects present in the networks. The higher the Z-score, the higher the number of objects
from the data set.
FIG. 3. Pathway analysis of endometrial androgen target gene set. Note 12 of 15 androgen-regulated genes identified by in silico screening (indicated with
multicolored circles) were predicted to interact in a single Metacore pathway centered on AR; intermediate molecules are indicated to show putative intermediate
signaling molecules. Key shows the functional classification of the target genes and the arrows indicate predicted regulation (red, negative; green, positive).
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capable of binding ligand activated androgen receptors
(11, 12) and has enabled us to identify, for the first time,
a group of androgen-regulated genes expressed in primary
hESC. Our strategy included data sets based on ChIP-on-
chip (11, 12) conducted using in prostate cancer-derived
epithelial cells treated for short duration with androgen.
We included the ChIP data sets because they provided a
stringent, unbiased way of focusing on genes that were
direct targets of androgen action; unfortunately, ChIP
data sets for androgen-treated endometrial cells were not
available. Only a small number of genes were identified as
common to all of these data sets reflecting differences in
tissue/cell context.
One unexpected finding was that treatment of primary
hESC with DHT resulted in a transient but significant
reduction in expression of most of the mRNA encoded by
our androgen target gene set. Consistent with the likely
differences in availability of modulators of androgen ac-
tion (coactivators/corepressors) between the AR-positive
cells from endometrium (primary stroma) and those used
for the ChIP arrays (transformed AR positive prostatic
epithelial cells), four genes (ACSS2, CITED2, MAOA,
PPFIBP2) showedDHT-dependent changes in expression
that were opposite in the two cell types [Table 1 (11, 17)].
Notably, the regulation of three of our androgen target
gene set, namely PRUNE2, PMAIP1, and ACSS2, has
never been investigated in the context of endometrial func-
tion. Promoter analysis identified multiple binding sites
for both AR and Sp1 and pathway analysis (see Fig. 3)
supported a role for Sp1 in mediating AR-dependent
changes in expressionof EDNRBandACSS2. In this study
we focused on the impact of androgens on stromal cells
recovered from the functional layer of the endometrium
during the proliferative phase at a time when AR is not
expressed in epithelial cells (Supplemental Fig. 1). How-
ever,wedid detect expressionofMAOA,CD44,CITED2,
PRUNE2, and PMAIP1 in endometrial epithelial cells by
immunohistochemistry, and therefore, further studies are
required to determine whether androgens also have an
impact on their expression in this cell type.
Analysis of the androgen target gene set withMetacore
software (GeneGo) revealed a strong association with pro-
cesses regulating programmed cell death (Table 2). Apopto-
sis is an important regulator of endometrial function, with
reports that it occurs predominantly in the late secretory
and menstrual phases associated with alterations in the
expression of Bcl-2 and Bax (23). Two members of our
target gene set,PRUNE2 (BMCC1) andPMAIP1, encode
proapoptotic proteins not previously investigated in the
context of endometrial function. PRUNE2 (BMCC1) is
highly expressed in the nervous system; although some
studies have reported androgen regulation in prostate can-
cer cells (24), this has been disputed (25). PMAIP1, also
known as NOXA (Latin for damage), encodes a Bcl-2
homology 3-only member of the Bcl-2 family of proteins.
The protein has been implicated in controlling cell death
pathways in several cell types by virtue of competitive
binding to proteins including the antiapoptotic proteins
Bcl-2 protein A1 Bcl-xL and MCL1 (26). In neuroblas-
toma cells, gene knockdown of PMAIP1 significantly re-
duces apoptosis (26). Expression of PMAIP1 can be re-
pressed by glucocorticoids in lymphoblasts of children
TABLE 3. Subnetworks within the candidate gene set and associated processes identified by androgen candidate
gene ontology identified using Metacore
Network GO processes P value Z-score
AR, CD44, EDNRB, CITED2, gastrin Response to stress, regulation of
catalytic activity
3.00e-32 86.27
PDGF-R-, CITED2, CD44 Response to hormone stimulus,
regulation of locomotion
7.21e-20 56.87
AR, CITED2, CD44, PMAIP1 Regulation of apoptosis,
regulation of programmed cell
death, regulation of
developmental process
2.14e-14 43.52
ACSS1, gastrin, pyrophosphate cytoplasm,
acetyl-CoA cytoplasm
Acetyl-CoA biosynthetic process,
IL-8 production
1.24e-08 43.12
EDNRB, HGD, TRH receptor, c-Src, connexin 43 Dopamine receptor signaling
pathway, regulation of
nucleotide biosynthetic process
3.06e-07 25.93
CITED2, ACSA, EDNRB, HNF4-, HIF1A Developmental process, response
to hypoxia
2.52e-07 26.76
Note that the term target indicates the number of candidate genes/proteins/compounds (objects) in a data set that are associated with a
given network/process. The P value (the probability of a random intersection) indicates a measure of relevance of the intersection between a
gene/protein and an entity in a particular ontology. The lower the P value, the higher is the nonrandomness of finding such intersection. The
Z-score ranks the networks with regard to the number of objects present in the networks. The higher the Z-score, the higher the number of
objects from the data set. GO, Gene ontology.
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with acute lymphoblastic leukemia (27), consistent with
detection of a putative glucocorticoid response element in
our TRANSFAC analysis.
Conversely, introduction of AR intoAR-negative pros-
tate cancer cells is reported to up-regulate expression of
PMAIP1 (28), highlighting the importance of cell context
in the regulation of this gene. Although initial studies re-
ported that PMAIP1 is a primary p53 response gene, it is
now apparent that multiple signals can induce its expres-
sion (reviewed in Ref. 29). Reduced expression of
PRUNE2 andPMAIP1 in the endometrium in response to
androgens is consistent with reports that the amount of
apoptosis is very low in the endometrium of patients with
PCOS (30), a condition associated with elevated circulat-
ing androgens, elevated expression of endometrial AR,
and infertility (6). CD44, the only gene identified as up-
regulated by androgen action in our primary stromal cells,
has also been implicated in regulatory pathways involving
the tumor suppressor p53. Its overexpression antagonizes
the tumor-suppressive apoptotic and growth-inhibitory
actions of p53 in mammary epithelial cells (31). Stromal
cell decidualization during the secretory phase is associ-
atedwith reduced expressionofAR in the functional layer,
but expression in the basal compartment is maintained
(Supplemental Fig. 1). These temporal and spatial differ-
ences in the pattern of expression of AR could result in
variations in expression of androgen-regulated genes in
the endometriumandmayprotect basal stromal cells from
apoptosis.
In addition to those genes implicated in control of ap-
optosis and/or associated with the activities of the tumor
suppressor p53 genes, several of the genes we have iden-
tified as androgen regulated in endometrial stromal cells
have also been implicated in development of cancers. For
example, SHCBP1 (SHC SH2 binding protein 1) has been
cited as one of a panel of six markers for the diagnosis of
early cervical cancer (32). PDGFRL, a gene that encodes
a secreted protein with significant sequence homology to
the ligand-binding domain of platelet-derived growth fac-
tor receptor-, has been proposed as a tumor suppressor
(33). CITED2, a CBP/p300-dependent transcriptional co-
activator,was associatedwith increased expressionofma-
trix metalloproteinase (MMP) 13 and enhanced invasive-
ness of colon cancer cells (34). All three genes have been
detected in uterine tissue. For example, Kim et al. (35)
reported that expression of SHCBP1was down-regulated
in endometrium recovered during the proliferative phase
fromwomenwith PCOS compared with controls, a result
consistent with our novel data demonstrating a striking
and significant reduction inhESCtreatedwithDHT.Talbi
et al. (15) have reported that expression of PDGFL and
CITED2 were cycle dependent, and studies in mice iden-
tifiedCited2 as one of a group of genes up-regulated in the
uterus 4 h after progesterone treatment (36).However,we
believe the current study is the first to report that these
genesmight be targets for androgen actionwithin the stro-
mal compartment of the human endometrium. Data
herein provide novel insight into the mechanisms that
might contribute to the increased risk of endometrial can-
cer observed in women with PCOS (7).
Endometriosis is a chronic condition characterized by
the presence of endometrial tissue outside the uterine cav-
ity and, like PCOS and endometrial hyperplasia, has been
FIG. 4. Treatment of hESC with DHT alters apoptosis and
proliferation. A, Apoptosis as measured by caspase-3/7 assay in cells
treated with staurosporine. Note addition of DHT had a significant
impact (*, P  0.05) on the rate of apoptosis when compared with
controls but that the impact of DHT was blunted in the presence of E2
(n  4). B, Wound-healing assay. Addition of DHT had a significant
impact (*, P  0.05) compared with its vehicle control (ethanol),
whereas flutamide alone had no impact compared with vehicle
(methanol) and pretreatment of cells with flutamide blocked the DHT-
dependent reduction in wound closure. DHT, 108 M; flutamide, 105
M; n  6.
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associated with a progesterone-resistant phenotype (37).
The synthetic androgen, Danazol (17-ethinyl testoster-
one) is an effective treatment for pain associated with en-
dometriosis but is no longer used due to unacceptable side
effects (38). Although disturbances in androgen-depen-
dent gene expression have not been investigated in the
context of this disease, it is notable that both AR and
5-reductase enzymes have been detected in pelvic endo-
metriosis (39). Altered expression of three of the genes in
our androgen target set has also been recorded in women
suffering from endometriosis. Cells recovered from men-
strual effluent of women with endometriosis are reported
tohave increased expressionofCD44splice variants.Cells
from the endometrium of women with endometriosis are
reported to exhibit increased adherence to peritoneal me-
sothelial cells (40) and reduced expression ofMAOA and
CITED2 (37). It has been suggested that alterations in
expression of MMP in endometriotic lesions would favor
disturbances in tissue invasion/remodeling within the en-
dometriotic tissue (41); expression of MMP10 has not
been investigated to date and would merit further inves-
tigation in these patients.
In conclusion, using rigorous bioinformatics to com-
pare data sets between species and between tissues, we
have identified a small cohort of androgen-responsive
genes expressed in the human endometrium. Pathway
analysis and functional assays suggest androgen-depen-
dent changes in gene expression may have a significant
impacton stromal cellmigrationandsurvival in this tissue.
These novel data provide the platform for further inves-
tigations on the role of circulatory or local androgens in
the regulation of endometrial function that will require
studies on intact tissue in which the dynamics of stromal-
epithelial interactions are maintained. These data identify
androgens as candidates in the pathogenesis of common
endometrial disorders including PCOS, endometrial can-
cer, and endometriosis.
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